Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration

Sponsor
Instituto de Olhos de Goiania
Study ID
NCT01014468
Phase
PHASE3
Status
Unknown

Conditions

  • Age Related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To report the short term anatomic and visual acuity response after intravitreal injection of bevacizumab and ranibizumab in patients with choroidal neovascularization secondary to age-related macular degeneration.

Key Dates

First listed
Nov 17, 2009
Start date
Mar 31, 2009
Status verified
Nov 2011
Primary completion
Nov 30, 2009
Completion
Feb 29, 2012

Study Design

Enrollment
500 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Ranibizumab
    Intravitreal injection of Ranibizumab (3 monthly injection followed by monthly injections as long as required)
  • Active Comparator: Bevacizumab
    Intravitreal injection of Bevacizumab (3 monthly injection followed by monthly injections as long as required)

Primary Outcome Measure

Vision change Anatomical changes (Regression of NVE, CNVM, reduction in macular thickness) Electrophysiological changes (ERG, VEP ) [ Time Frame: 6 months ]

Related Studies